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ABSTRACT: Mutations in the FERMT1 gene (also known 
as KIND1), encoding the focal adhesion protein kindlin- 
1, underlie the Kindler syndrome (KS), an autosomal 
recessive skin disorder with an intriguing progressive 
phenotype comprising skin blistering, photosensitivity, 
progressive poikiloderma with extensive skin atrophy, and 
propensity to skin cancer. Herein we review the clinical 
and genetic data of 62 patients, and delineate the natu-
ral history of the disorder, for example, age at onset of 
symptoms, or risk of malignancy. Although most muta-
tions are predicted to lead to premature termination of 
translation, and to loss of kindlin-1 function, significant 
clinical variability is observed among patients. There is an 
association of FERMT1 missense and in-frame deletion 
mutations with milder disease phenotypes, and later onset 
of complications. Nevertheless, the clinical variability is 
not fully explained by genotype–phenotype correlations. 
Environmental factors and yet unidentified modifiers may 
play a role. Better understanding of the molecular patho-
genesis of KS should enable the development of prevention 
strategies for disease complications.
KEY WORDS: FERMT1; epidermolysis bullosa; kindlin;
poikiloderma; blister; fermitin
Background
Kindler syndrome (KS; MIM# 173650) is caused by mutations
in FERMT1 (also known as KIND1; MIM# 607900), the gene en-
coding kindlin-1 [Fine et al., 2008; Jobard et al., 2003]. KS is a
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rare autosomal recessive skin disorder with an intriguing progres-
sive phenotype comprising skin blistering, photosensitivity, pro-
gressive poikiloderma, and extensive skin atrophy [Lai-Cheong and
McGrath, 2010]. Additional clinical features include gingival
erosions, ocular, esophageal, gastrointestinal and urogenital in-
volvement, and an increased risk of mucocutaneous malignancy
[Lai-Cheong and McGrath, 2010]. To date, about 150 KS patients
with FERMT1 mutations have been described in the literature. All
46 mutations reported so far are predicted to lead to premature ter-
mination of translation and to loss of the kindlin-1 protein or of its
function [Lai-Cheong and McGrath, 2010; Techanukul et al., 2011].
The clinical and genetic aspects of the disease have recently been re-
viewed [Lai-Cheong and McGrath, 2010; Lai-Cheong et al., 2009],
but precise data on genotype–phenotype correlations and the nat-
ural history of the disorder, for example, age at onset of symptoms,
or risk of malignancy, still remain elusive.
The FERMT1 gene product, kindlin-1, is a member of the new
protein family of kindlins-1, -2, and -3. It is an epithelial-specific
protein expressed in the skin, periodontal tissues, and colon [Herz
et al., 2006; Kern et al., 2007; Petricca et al., 2009; Ussar et al., 2008].
In the skin, kindlin-1 is localized in basal epidermal keratinocytes
and exists in two forms, nonphosphorylated and phosphorylated
[Herz et al., 2006]. The four point one ezrin radixin and moesin
(FERM) and pleckstrin homology (PH) domains are involved in
molecular interactions, providing kindlin-1 the role of a focal ad-
hesion adaptor protein linking filamentous actin in the cell cortex,
to membrane proteins [Goult et al., 2009; Larjava et al., 2008]. In
KS skin, disorganized keratinocytes lose their proper architecture,
polarization, and the boundary to the dermis and exhibit mini-
mal proliferation. In vitro, loss of kindlin-1 function is associated
with abnormal cell shape and, functionally, cell adhesion, spreading,
proliferation, and directed motility are perturbed [Herz et al., 2006;
Petricca et al., 2009; Ussar et al., 2008]. These deficits stem from im-
paired functions of focal adhesions (FA), which assure the anchor-
age of the cytoskeleton to integrin-associated signaling platforms.
Kindlin-1 is a member of the intracellular ß1 integrin-associated
signalling complex and, thus, of FA, but the function of kindlins
as activators of β integrins together with talin is still controversial
[Harburger and Calderwood, 2009; Moser et al., 2009]. Whereas FA
and β1 integrin functions have been extensively studied in cultured
cells, their significance and functionality in vivo in the skin and
mucosa remain unclear. KS is the first FA skin disorder known so
far and, therefore, represents a genetic model to understand the role
of FA protein complexes in tissues in vivo.
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Figure 1. FERMT1 gene, kindlin-1 protein, and the spectrum of mutations. A: Schematic representation of the FERMT1 gene comprising 15
exons (black boxes). The mutations described in this study—in red, novel mutations and in blue, known mutations—and in the literature (in
black) are depicted. B: The kindlin-1 protein with four point one ezrin radixin and moesin (F) and pleckstrin homology domains, phosphorylated
serine residues and β integrin binding region is shown. Note the location of the novel missense mutations and in-frame deletions reported in this
study.
Here we review the FERMT1 mutational database and extend
it with 10 novel mutations, including the first FERMT1 missense
and in-frame deletion mutations associated with KS. Moreover, we
evaluate the progressive phenotype and complications of KS in a
cohort comprising 62 patients with defined FERMT1 mutations. To
the best of our knowledge, this is the largest cohort systematically
analyzd so far.
Variants in the FERMT1 Gene
All FERMT1 sequence changes published thus far, together with
novel variants characterized in our laboratories, are represented in
Figure 1A and in the Supp. Table S1. The genotypes and phenotypes
of 62 patients included in the study are listed in Table 1.
The mutational analysis of KS in the present cohort was
performed as described [Has et al., 2006]. Briefly, genomic
DNA extracted from peripheral lymphocytes was used for PCR
amplification of the entire coding region and exon–intron bound-
aries of the FERMT1 gene [Has et al., 2006]. The PCR prod-
ucts were processed for automated nucleotide sequencing in an
ABI 3130XL genetic analyzer (ABI, Darmstadt, Germany). DNA
sequences were compared to the reference sequences from the
NCBI Entrez Nucleotide database (NM_017671.4; AL118505.17).
Nucleotide numbering reflects cDNA numbering with +1 corre-
sponding to the A of the ATG translation initiation codon in
the reference sequence (www.hgvs.org/mutnomen). The initia-
tion codon is codon 1. The sequence variants were confirmed by
resequencing of PCR products obtained from a second amplifi-
cation reaction. For the novel allelic variants, at least 100 (for
missense mutations 200) control chromosomes were screened by
direct sequencing. Prediction of splice sites was performed with Net-
Gene2 (http://www.cbs.dtu.dk/services/NetGene2/), whereas for
prediction of the consequences of amino acid substitutions and
single amino acid deletions, PolyPhen (http://genetics.bwh.harvard
.edu/pph/) and Mutation Taster (http://neurocore.charite.de/
MutationTaster/index.html) were employed. The effects of the
c.1371+4A>G splicing mutation were also tested by reverse
transcriptase (RT)-PCR analysis of the total RNA extracted from
cultured keratinocytes of patient 4, using primers and PCR condi-
tions reported previously [Has et al., 2006].
This mutational survey disclosed 34 distinct FERMT1 sequence
variants: 10 deletions, five duplications or insertions, one insertion
or deletion, seven splice-site mutations, nine nonsense mutations,
and two missense mutations (Fig. 1A; Table 1). Ten previously un-
known mutations were found, including two nonsense mutations,
two splice-site mutations, one deletion or insertion, three small
deletions, and two missense mutations.
The novel mutations p.Glu351X and p.Gln460X increase the per-
centage of nonsense mutations in the FERMT1 mutational database
to 37.5% (21 of 56). The c.1729del (p.Ser577AlafsX14) mutation
results in a premature stop codon that deletes most of the FERM
3 domain of kindlin-1 or, more likely, triggers mRNA degradation
via nonsense-mediated decay mechanisms. The splice-site muta-
tion c.1264+1G>A changes the obligate G nucleotide of the splice
donor site of exon 10, whereas c.1371+4A>G is predicted to abolish
the splice donor site of exon 11 (NetGene2). Consequently, exon
11 could be skipped, or an upstream cryptic splice site located in
exon 11 (TGgtatga) could be activated leading to skipping of 32 nu-
cleotides; RT-PCR analysis and sequencing of the resulting cDNA
product confirmed the latter prediction (not shown), which results
in a frame shift and premature termination of translation. The dele-
tion insertion c.152-2delAGinsCT mutates the invariant AG dinu-
cleotide of the splice acceptor site of exon 3 and, therefore, interferes
with the splicing process.
Here we defined the first FERMT1 in-frame deletions:
p.Arg100del and p.Ile623del. Both were excluded in normal con-
trol chromosomes and were predicted to be disease relevant (Muta-
tion Taster). Arginine 100, located within the FERM 1 subdomain
(Fig. 1B), is conserved in mammalians, chicken, and Xenopus lae-
vis. Although the precise consequence of this mutation remains to
be established, the N-terminal region of kindlins is believed to be
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important for interaction with binding partners, such as integrins,
migfilin, and integrin linked kinase [Goult et al., 2009; Larjava
et al., 2008]. The in-frame deletion of isoleucine 623 affects the
FERM 3 subdomain close to the binding site for β1 integrin
[Harburger et al., 2009] (Fig. 1B).
Importantly, we also report the first amino acid substitutions
associated with a KS phenotype: p.Ser400Pro and p.Trp559Arg. Both
mutations were excluded in 200 control chromosomes and were
predicted to be disease causing by both Polyphen and Mutation
Taster. However, the molecular consequences of these amino acid
substitutions remain to be established. Serine 400 is conserved in
mammalians, chicken, X. laevis, and in human kindlin-2, and it
is located in the PH domain, which is considered to be important
for protein–protein interactions (Fig. 1B). Tryptophan 559 within
the FERM 2 domain is widely conserved among different species
(Fig. 1B). The mutation replaces tryptophan, a nonpolar neutral
amino acid, with arginine, which is polar and positively charged.
This substitution is likely to perturb protein folding of the FERM
domain and thus affect its function as the binding ligand for actin
cytoskeleton.
Genotype–Phenotype Correlation and Natural
History of KS
Sixty-two patients, 32 females and 30 males, originating from
different parts of the world were included in this survey. Ten pa-
tients were ≤10 years of age, 17 between 11 and 20 years of age, 24
between 21 and 45 years of age, and 10 were >45 years of age at
the time of recording the clinical data. In three cases, no detailed
information was available. The diagnosis was suggested by clinical
features, history, and morphological analyses of the skin, and con-
firmed by disclosure of FERMT1 mutations. To assess the severity
and the course of the disorder, the following clinical parameters
were recorded: skin blistering, photosensitivity, skin atrophy, and
poikiloderma, webbing of fingers and toes, pseudoainhum, extent
of mucosal involvement, and development of epithelial skin cancers
(Table 1).
Genotype–Phenotype Correlation
Thus far, two aspects have impeded assessment of genotype–
phenotype correlations in KS. First, because all previously reported
mutations were predicted to be null mutations leading to loss of
kindlin-1 and its functions, phenotypic variations could not be ex-
plained by the nature or the position of the mutation. The present
study describing the firstFERMT1missense mutations and in-frame
deletions enables the first true genotype–phenotype correlations in
KS. Patient 51, homozygous for p.Arg100del, and patient 53, ho-
mozygous for p.Ser400Pro, are mildly affected and have not de-
veloped epithelial skin cancer, in spite of both being in their fifties.
This suggests that mutations compatible with expression of mutated
kindlin-1 protein will translate into mild phenotypes, whereas null
mutations cause severe disease.
Second, the KS phenotype is progressive, evolving with age. Con-
sequently, the severity of the symptoms in patients of different ages
cannot be compared. Although all individuals with KS caused by
null mutations exhibit skin blistering, poikiloderma, and photosen-
sitivity, the variability of clinical presentation is evident, suggesting
a role for environmental and/or epigenetic factors. We have recently
shown that the cumulative effect of cell stress-inducing events may
play a decisive role in the outcome of the disease [He et al., 2011;
Heinemann et al., 2011]. Kindlin-1 deficient keratinocytes respond
to cell stress by upregulating the expression of cytokines, for ex-
ample, IL-20, IL-24, and TGF-β2. An inflammatory response and
activation of fibroblasts and their differentiation to myofibroblasts
in the dermis are initiated. These data suggest that repeated cycles
of epidermal cell stress, cytokine secretion, dermal inflammation,
and profibrotic processes underlie mucocutaneous fibrosis in KS
[Heinemann et al., 2011]. Skin and mucous membranes, which
form the barrier to the environment, are permanently exposed to
mechanical factors, UV irradiation, and pathogens. Increased envi-
ronmental noxae may explain the extent of symptoms in severely
affected KS patients described before [Has, et al. 2008a; Kern et al.,
2007; Mansur et al., 2007].
Natural History of KS
Systematic analysis of the clinical features in 59 patients revealed
the chronology of the onset of symptoms and complications in KS
and allowed delineation of the natural history of the disorder in this
cohort (Fig. 2; Table 1). Skin blistering was present in all (100%) KS
patients younger than 10 years (Fig. 3A), but progressively decreased
with age. Skin fragility was considered relatively mild in the adult KS
patients, since some of them reported not to get blisters even after
using adhesive tapes. Photosensitivity was assessed subjectively by
patients or parents. Seventy-six percent (45 of 59) reported mild
photosensitivity, but 24% (14 of 59) denied having problems with
sunlight. Skin atrophy of the dorsal aspects of the hands was the
first symptom indicative of KS in children, and was recognized as
early as at the age of 2 years (Fig. 3B and C). Poikiloderma was first
noted around the age of 10 years, and it progressed with age (Fig. 3D
and E). Sclerosing features of the hands and feet, such as webbing,
or pseudoainhum occurred only after the age of 10 years, but were
present already in 53% (9 of 17) of patients in the age group of
11–20 years. However, the severity seemed not to be exclusively age-
dependent. Cumulative mechanical stress may play an important
role. For example, patient 27 who was treated during her childhood
with tight bandages for her acral blisters had severe webbing and
sclerotic fingers. In the present cohort, epithelial skin cancer was
not diagnosed before the age of 45 years, but affected 70% (7 of 10)
of the patients older than 45 years. All patients developed squamous
cell carcinomas or precursor lesions, whereas basal cell carcinomas
were occasionally diagnosed.
Mucosal involvement is very common in KS. The oral mucosa
was most frequently affected, as observed in 85% (49 of 58) of the
patients. Symptoms related to esophageal affection were not noted
before the age of 10 years. Thereafter, they developed progressively
evolving from dysphagia to strictures requiring repeated dilatations,
affecting 53%, 67%, and 89%, of the patients in the age categories
of <20, 21–45, and >45 years, respectively (Fig. 2). Anal, urogeni-
tal, and ocular mucosa involvement occurred occasionally in adult
patients (Fig. 2). Intestinal involvement, that is, colitis induced by
epitheliolysis [Kern et al., 2007], was diagnosed in only 15% (9
of 58) cases. This is in contrast to the kindlin-1 knockout mouse,
which exhibited lethal intestinal involvement and a very mild skin
phenotype [Ussar et al., 2008].
Clinical Relevance
Knowledge of the natural history enables better and early recog-
nition of KS, and design of a prevention plan through adapta-
tion of the life style (e.g. elimination of UV exposure, skin care).
In KS, the phenotype evolves with improvement of skin blister-
ing with advancing age, similar to epidermolysis bullosa simplex
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Figure 2. Natural history of Kindler syndrome (KS) in the present cohort. The upper graph shows the age-dependent course of skin involvement
comprising skin blistering, photosensitivity, atrophy/poikiloderma, webbing/sclerotic changes of hands and feet, and epithelial skin cancer. The
lower graph depicts the age-dependent course of the mucosal involvement. [Color figure can be viewed in the online issue, which is available at
wiley.com/humanmutation.]
(Sprecher, 2010). There is no molecular explanation for this phe-
nomenon, but several hypotheses can be discussed. First, FA are
not major adhesive structures at the dermal–epidermal junction.
Therefore, compensatory mechanisms involving other supramolec-
ular adhesive structures, for example, hemidesmosomes could ex-
plain the amelioration of skin fragility. Second, with advancing age
patients learn to adapt their lifestyle (e.g. to avoid exposure to me-
chanical stress and sun, constantly apply intensive skin care), and
thus influence epigenetic effects. Third, based on personal observa-
tions, somatic genetic events may modify the course of the disease.
Revertant mosaicism refers to the occurrence of revertant or sec-
ond site mutations, which attenuate or abolish the effect of the
disease-causing mutations, thus leading to improvement of the skin
function.
Importantly, involvement of esophageal and genitourinary mu-
cosa is common, and clearly increases with age. The same applies to
the risk of nonmelanoma skin cancers. Almost all patients included
in this study developed premalignant and malignant skin lesions
after the age of 45 years, whereas in the general population, the inci-
dence rates for squamous cell carcinoma are 4.8/100,000 in men and
0.6/100,000 in women, in the same age group [Stang et al., 2003].
Early diagnosis and treatment of such conditions are essential for
prevention of severe progression [Arita et al., 2007; Emanuel et al.,
2006].
Noteworthy, a broad spectrum of differential diagnoses had been
considered in our patients, including dystrophic epidermolysis bul-
losa, epidermolysis bullosa simplex, xeroderma pigmentosum, and
systemic scleroderma. Conversely, patients with particular forms of
junctional epidermolysis bullosa, and EBS with mottled pigmenta-
tion were suspected to suffer from KS, because of substantial overlap
in clinical and morphologic findings.
Importantly, the majority of KS patients reported thus far are ho-
mozygous for their mutations. They are predominantly offspring of
consanguineous marriages, or originate from isolated populations
(e.g. Native Americans from Panama [Penagos et al., 2004; Siegel
et al., 2003], immigrants in Brazil [Martignago et al., 2007]). Some
mutations seem to affect hot spots or to have occurred long time
ago, being disseminated in populations (e.g. g.70250_74168del in
southern Italy [Has et al., 2006], g.80929_89169del in the Balkans,
c.676dup in the former Yugoslavia reported here, Table 1). It is
difficult to assess the global incidence of KS. Thus far, about
150 patients have been reported in the literature, but the number
of affected persons is certainly higher, because KS is often misdiag-
nosed and underestimated.
Mutation analysis remains the gold standard of KS diagno-
sis. However, since skin blistering is a dominant symptom in
childhood—for this reason KS is considered a subtype of epi-
dermolysis bullosa—morphological analysis of a skin biopsy is
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Figure 3. Clinical features of KS. A: Acral blisters in a 2-year-old patient. B: Incipient skin atrophy in the same patient. C: Pronounced
atrophy on the dorsal aspects of the hands in an 8-year-old patient. D: Poikiloderma, cigarette-paper-like atrophy, and webbing of the fingers
at the age of 28 years. E: Generalized poikiloderma in a 53-year-old patient. F: Severe involvement of the oral mucosa in a 28-year-old KS
patient.
often the first diagnostic procedure performed. The indirect im-
munofluorescence (IIF) and transmission electron microscopy
(TEM) findings of irregular, branched, and interrupted base-
ment membrane are characteristic and indicative of KS and jus-
tify FERMT1 mutation analysis for confirmation of the suspected
diagnosis.
Here, in the majority of cases, IIF staining was performed to
support the genetic diagnosis and explore the consequences of
kindlin-1 mutations on the morphology of the skin, in particu-
lar of the dermal–epidermal basement membrane. IIF staining was
performed on 5-μm cryosections of KS and normal skin. Skin sec-
tions were blocked with 0.1% BSA/TBS for 30 min and treated with
primary antibodies to collagen IV (Col IV-22, Abcam), collagen
XVII [Hofmann et al., 2009], pankeratin (Dako, Hamburg, Ger-
many), BM165 to human laminin α3 chain (a gift from Dr. P. Rous-
selle, Lyon, France), 6F12 to human laminin β3 chain (a gift from
Dr. RE Burgeson, Cutaneous Biology Research Center, Harvard
Medical School, Cambridge, MA), GB3 to laminin γ2 chain (a gift of
Dr. G. Meneguzzi, Nice, France), and LH 7.2 to the NC1-domain
of collagen VII (Sigma, Taufkirchen, Germany), and kindlin-1
[Herz, et al., 2006]. The secondary antibodies were fluorescein
isothiocyanate-labelled anti-mouse or anti-rabbit IgG. The signals
were visualized with epifluorescence microscopy (Zeiss Axio Im-
ager, Zeiss). Typically, thickened and interrupted basement mem-
brane labelling for laminin-332, collagen IV and collagen VII was
observed (Fig. 4A). In some cases, kindlin-1 staining was performed
and revealed absence of a signal at the dermal–epidermal junction,
although the polyclonal sera give a background staining in the entire
epidermis (Fig. 4B).
As morphologic features at light microscopic level, epidermal
atrophy and microblisters at the dermal–epidermal junction were
noted. In five cases, TEM demonstrated focal widening of the lamina
lucida (microdetachments), reduplications of the lamina densa and,
occasionally, moderately hypoplastic hemidesmosomes.
FERMT1 mutations are found in patients with typical clini-
cal findings of KS and/or typical morphological aspect in IIF or
TEM. In our experience, in cases without FERMT1 mutations,
clinical and skin morphological data are usually lacking, mak-
ing the diagnosis rather difficult. Moreover, most antibodies to
kindlin-1 give high levels of background, and therefore, loss of
the expression of the protein cannot be reliably established by
IIF of skin samples. In cases with strong suspicion of KS, in
whom no FERMT1 mutations are disclosed by direct sequenc-
ing, and large deletions are excluded, extensive analyses of RNA
and proteins extracted from cultivated keratinocytes should shed
light onto the molecular disease mechanisms. However, the evalua-
tion of the pathogenic role of missense mutations requires further
investigations.
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Figure 4. Morphological abnormalities of KS skin. Immunofluores-
cence staining of control and KS skin with antibodies to collagen IV and
kindlin-1. A: In contrast to the linear deposition of collagen IV at the
epidermal basement membrane in control skin, an irregular and inter-
rupted staining pattern is seen in KS skin. B: Note the linear localization
of kindlin-1 at the dermal–epidermal junction in control skin (arrow),
and its absence in KS skin (the interrupted line depicts the dermal–
epidermal junction). The antibody gives a background staining in the
entire epidermis.
Future Prospects
Future research will be directed toward better understanding of
molecular disease mechanisms, including genotype–phenotype cor-
relations and modifiers of the phenotype, making use of mouse
models, recombinant systems, or proteomics approaches. The con-
sequences of missense mutations and in-frame deletions, which
seem to account for milder phenotypes, remain to be elucidated.
Prevention of complications and treatment prospects might arise
from identification of modifying factors. A further goal is the clin-
ical and genetic delineation of KS-like phenotypes, which are not
caused by FERMT1 mutations. In such cases, identification of new
disease-causing genes will be possible by whole-exome sequencing
in nuclear families [Glazov et al., 2011].
A locus-specific mutation database is available at: http://
www.LOVD.nl/FERMT1.
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